Update: Big in Japan?
Following analysis of the Phase III data of evofosfamide (TH-302) in unresectable or metastatic pancreatic cancer patients, which failed on an intent-to-treat basis (p=0.0588), Threshold Pharmaceuticals has announced that the drug seemed to demonstrate impressive efficacy among the patients in Japan. Overall survival in the Japanese subset was 13.6 months vs 9.1 months in the control arm (p=0.0106). The company is currently seeking a partner in Japan and reaching out to the Pharmaceutical and Medical Device Agency (PMDA) to understand the potential path forward.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.